Literature DB >> 2180716

Calcium antagonists in migraine and vertigo. Possible mechanisms of action and review of clinical trials.

J Olesen1.   

Abstract

Three primary mechanisms have been suggested as an explanation of migraine; a neuronal event, a vascular event and a mechanism focussing on the trigeminal nerve and its supply to intra- and extracranial blood vessels. None of these theories has been adequately proven yet. A neuronal point of impact, rather than a vascular one, seems to be responsible for migraine prophylaxis with calcium antagonists. Primarily vasoactive substances such as nimodipine are not or only marginally effective, whereas flunarizine with a limited vascular activity is effective. Data on other calcium antagonists are insufficient to conclude on a migraine-prophylactic activity. The only calcium antagonist that has been extensively tested for vertigo is flunarizine. In placebo-controlled trials, the drug showed to be effective in labyrinthine vertigo. The mechanism behind this effect is unclear.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2180716     DOI: 10.1159/000117189

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  4 in total

1.  Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial.

Authors:  Anjali Lepcha; Sophia Amalanathan; Ann Mary Augustine; Amit Kumar Tyagi; Achamma Balraj
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-10-29       Impact factor: 2.503

Review 2.  Association of cinnarizine and betahistine in prophylactic therapy for Ménière's disease with and without migraine.

Authors:  R Teggi; O Gatti; V Sykopetrites; S Quaglieri; M Benazzo; M Bussi
Journal:  Acta Otorhinolaryngol Ital       Date:  2014-10       Impact factor: 2.124

3.  Optimizing prophylactic treatment of migraine: Subtypes and patient matching.

Authors:  Michel Dib
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

4.  Effect of a fixed combination of nimodipine and betahistine versus betahistine as monotherapy in the long-term treatment of Ménière's disease: a 10-year experience.

Authors:  D Monzani; M R Barillari; M Alicandri Ciufelli; E Aggazzotti Cavazza; V Neri; L Presutti; E Genovese
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-12       Impact factor: 2.124

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.